Information Provided By:
Fly News Breaks for December 19, 2019
BSX
Dec 19, 2019 | 07:24 EDT
Needham analyst Mike Matson downgraded Boston Scientific to Buy from Strong Buy with a $53 price target. The analyst notes that while he sees potential for "modest" revenue and earnings upside in 2020 thanks to the company's strong product cycle, he does not anticipate further revenue growth acceleration beyond high single digits. Matson adds that after a 700bps improvement in Boston Scientific operating margins since 2012, there is less room for further upside from current levels.
News For BSX From the Last 2 Days
BSX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.